OTTAWA Canada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.
Procurement Minister Anita Anand said Ottawa was “very, very intensely negotiating” multiple deals with a number of other potential domestic and international vaccine suppliers, but did not give details.
There are no approved vaccines for COVID-19, but 19 vaccines are being tested in humans around the world.
“We all want a silver bullet but unfortunately that’s not the case,” Anand told a news conference. Other measures would be needed, such as buying more protective equipment and investing in medicines to alleviate the symptoms of sufferers.
Moderna will provide its mRNA-1273 vaccine candidate. Pfizer – working with German biotech firm BioNTech SE – said separately it planned deliveries of the BNT162 mRNA-based vaccine candidate over the course of 2021.
All potential vaccines will require Health Canada regulatory approval, Anand said, adding that her ministry was procuring the equipment supplies needed to perform the final manufacturing and packaging stages of vaccine production in Canada.
Anand described the Pfizer and Moderna experimental vaccines as “very promising” but noted much work remained.
“Any potential vaccine candidate will take time to develop, properly test, mass manufacture and properly distribute,” she said, declining to say how much the deals were worth.
Separately, Moderna said smaller volume agreements had been priced in the range of $32 U.S. to $37 per dose while larger volume agreements would be priced lower.
Innovation Minister Navdeep Bains said Ottawa was investing C$56 million ($42 million) to support clinical trials by VBI Vaccines Inc . Canada said in April it would spend C$1.1 billion to bolster vaccine research, clinical trials and national testing.
($1=1.3247 Canadian dollars)
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment